SCHEMBL23536128

SCHEMBL23536128

CN(C)S(=O)(=O)c1ccc(C(C)(C)N)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
ALDH1A1 P00352 4/20 0.52
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TRPV4 Q9HBA0 1/20 0.49
LOX P28300 1/20 0.45
MAPT P10636 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ABCC9 O60706 1/20 0.43
ABCC8 Q09428 1/20 0.43
KCNJ11 Q14654 1/20 0.43
KCNJ8 Q15842 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409342 0.83 ALDH1A1 (0.57) LMNAALDH1A1HTTSMN1; SMN2TRPV4
SCHEMBL13465623 0.82 TRPV4 (0.67) LMNAALDH1A1HTTSMN1; SMN2TRPV4
SCHEMBL19185561 0.80 ALDH1A1 (0.52) LMNAALDH1A1HTTSMN1; SMN2TRPV4
SCHEMBL20680957 0.77 KIF11 (0.59) MAPTCA12CA1CA2CA3
SCHEMBL14016158 0.77 ENPP2 (0.48) ALDH1A1LOX
SCHEMBL7873867 0.77 CA9 (0.55) ALDH1A1SMN1; SMN2ABCC9ABCC8KCNJ11
SCHEMBL10590602 0.76 LMNA (0.52) LMNAALDH1A1HTTSMN1; SMN2TRPV4
SCHEMBL21244024 0.74 LMNA (0.59) LMNAALDH1A1HTTSMN1; SMN2LOX
SCHEMBL519624 0.74 LMNA (0.59) LMNAALDH1A1HTTSMN1; SMN2LOX
SCHEMBL8157323 0.74 CA2 (0.59) LMNAALDH1A1HTTSMN1; SMN2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 LMNA 3324/4885ALDH1A1 3737/4885HTT 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.